We are excited to announce Advent International will join existing shareholder Nautic Partners as a new investor in Genoa, a QoL Healthcare Company. The addition of Advent as a new investor will provide the company with further resources as it continues to enhance its service offering and expand its geographic footprint. For the full press release, click here.
Tardive Dyskinesia – a neurological disorder linked to prolonged use of antipsychotic medications – impacts over 600,000 individuals each year. Did you know that 50% of consumers taking TD medication...
A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...
Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...
For qualified clinics and organizations, the 340B Drug Pricing Program offers savings on prescription drug costs, helping boost offerings and outcomes for people who need it most. Wondering if your...